GAITHERSBURG, Md., April 22, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced two key oral presentations and a poster presentation highlighting AutoloGel® will be made at the Symposium on Advanced Wound Care (SAWC) Spring Meeting, being held April 23-27, 2014, at the Gaylord Palms Hotel & Convention Center, in Orlando Florida. Cytomedix will also have an exhibition booth at the meeting (#901).
"We are excited to be participating in this year's Symposium on Advanced Wound Care meeting, which is one of the largest meetings in the U.S. for health care professionals to discuss and learn about the latest advances in wound care," said Martin Rosendale, Chief Executive Officer of Cytomedix. "As we proceed with the launch of AutoloGel, our presence at medical conferences provides an opportunity to showcase the value of our product to a wide audience of healthcare practitioners."
|Oral Presentation Details:|
|Date:||Friday, April 25th|
|Time:||4.45 – 5.45 pm|
|Session:||Session 32: SAWC Spring Oral Abstract Presentations|
|Title:||Platelet Rich Plasma Gel Consistently Reduces Pressure Ulcer Size|
|Speaker:||Carelyn P. Fylling, RN, MSN, CWS, CLNC|
|Vice President, Professional Services|
| Synopsis: ||Pressure ulcer area and volume were reduced with each application of a unique autologous platelet rich plasma gel formulation. Using 2 separate analyses, in 3 ½ weeks, pressure ulcers reduced by 46-50% in area and 60-67% in volume. The observed rate of reduction is in contrast with the previous 46 weeks of non-healing. This formulation of autologous platelet rich plasma gel can be a tool to consistently reduce the size of pressure ulcers.|
|Date:||Saturday, April 26|
|Time:||10:30am - 11:30am|
|Session:||Session 34: Fundamental Clinical Practice|
|Title:||Pressure Ulcer 2: Spinal Cord Injury|
|Speakers:||Laurie Rappl, PT, DPT, CWS|
|Clinical Specialist – Cytomedix, Inc.|
|Lance L. Goetz, MD|
|Hunter Holmes McGuire VA Medical Center|
|Julie Hill, PT|
|Shepherd Spinal Center|
| Synopsis: ||Pressure ulcers are a major complication of patients with spinal cord injury (SCI) and have a significant effect on general health and quality of life. This session will examine the pathophysiology of pressure ulcer development in the patient with SCI and issues specific to this population including: recurrence, altered anatomy, risk assessment, and prevention.|
|Poster Presentation Details|
|Dates & Times:|
|Friday, April 25 - 7:30 AM – 6:00 PM|
|Friday, April 25 - 7:15 PM – 8:30 PM|
|Saturday, April 26 -- 7:30 AM – 6:00 PM|
|Title:||Poster Number CS_058: Platelet Rich Plasma Gel Consistently Reduces Pressure Ulcer Size|
|Authors:||Carelyn P. Fylling, RN, MSN, CWS, CLNC|
|Vice President, Professional Services - Cytomedix, Inc.|
|Laurie Rappl, PT, DPT, CWS|
|Clinical Specialist – Cytomedix, Inc.|
About the Symposium on Advanced Wound Care
The Symposium on Advanced Wound Care or SAWC (held each year in the spring and fall) is the official conference for the Association for the Advancement of Wound Care (AAWC). The symposium is committed to providing the highest level of clinical wound education with continuing education credits and information to physicians, podiatrists, nurses, physical therapists and allied health professionals dedicated to the advancement of wound management and wound healing. The SAWC also hosts a major exhibition of wound products and services for wound care professionals. For further details, please go to http://www.sawc.net/spring/.
The AutoloGel System utilizes a proprietary unique technology that enables the rapid isolation and activation of PRP from a patient's own blood. The PRP is subsequently processed to produce a bioactive gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. In normal healing, platelets migrate from the blood into the wound site where they serve as the primary source of growth factors for effective wound healing. In chronic wounds, blood supply may be impaired and the delivery of platelets is impeded, disallowing adequate concentrations of growth factors. The AutoloGel System is used at the point-of-care and is the only PRP system cleared by the U.S. Food and Drug Administration for use on exuding wounds, such as leg ulcers, pressure ulcers and diabetic ulcers, and for the management of mechanically or surgically-debrided wounds. Cytomedix's clinical studies have shown that AutoloGel rapidly and more effectively improved healing compared with control-treated wounds. This has been demonstrated in a variety of clinical studies including a systematic review of 21 comparison studies and a number of other observational and case series publications as well.
Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care. The Company markets the AutoloGel® System (AutoloGel.com), a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds. For additional information please visit cytomedix.com.
Safe Harbor Statement – Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully execute its Angel and AutoloGel sales strategies, its expectations relating to the size of the US wound care market as well as its ability to establish and increase its sales and establish the Company's brand in such market, to achieve AutoloGel expected reimbursement rates in 2014 and beyond, and thereafter, the Company's ability to collect the data necessary for the grant of the unconditional coverage, the Company's ability to continue in its efforts to expand in the wound care market, its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatments, , to meet its stroke trial enrollment rates, to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company's ability to successfully integrate the Aldagen acquisition, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2013, as amended to date, and other subsequent filings. These filings are available at www.sec.gov.
CONTACT: Cytomedix, Inc. Martin Rosendale, Chief Executive Officer Steven A. Shallcross, EVP/Chief Financial Officer (240) 499-2680 (646) 597-6979 Investors Michael Rice LifeSci Advisors, LLC email@example.comSource:Cytomedix, Inc.